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The Cdc14 family of serine-threonine phosphatases antago-
nizes CDK activity by reversing CDK-dependent phosphoryla-
tion events. It is well established that the yeast members of this
family bring about the M/G1 transition. Budding yeast Cdc14
is essential for CDK inactivation at the end of mitosis and fis-
sion yeast Cdc14 homologue Flp1/Clp1 down-regulates Cdc25
to ensure the inactivation of mitotic CDK complexes to trigger
cell division. However, the functions of human Cdc14 homo-
logues remain poorly understood. Here we have tested the hy-
pothesis that Cdc14A might regulate Cdc25 mitotic inducers
in human cells. We found that increasing levels of Cdc14A de-
lay entry into mitosis by inhibiting Cdk1-cyclin B1 activity. By
contrast, lowering the levels of Cdc14A accelerates mitotic
entry. Biochemical analyses revealed that Cdc14A acts through
key Cdk1-cyclin B1 regulators. We observed that Cdc14A di-
rectly bound to and dephosphorylated Cdc25B, inhibiting its
catalytic activity. Cdc14A also regulated the activity of Cdc25A
at the G2/M transition. Our results indicate that Cdc14A
phosphatase prevents premature activation of Cdk1 regulating
Cdc25A and Cdc25B at the entry into mitosis.
In eukaryotes, periodic fluctuations in the activity of cyclin-
dependent kinases (CDKs)4 govern the cell division cycle by
controlling the precise timing and spatial distribution of
phosphorylation events, essential for cell duplication and the
maintenance of genomic stability (1–3). Different Cdk-cyclin
complexes form at specific cell-cycle stages and initiate the
events of the S and M phases. Thus, Cdk1-cyclin B complexes
are key regulators of mitosis in mammalian cells. Cdk1 kinase
activity drives cells into mitosis and governs early mitotic
events such as chromosome condensation, nuclear envelope
breakdown, and the assembly of the mitotic spindle (1, 4–6).
At metaphase, Cdk1-cyclin B complexes have completed their
main functions and are inactivated for cells to exit from
mitosis.
Like all CDKs, Cdk1 is subject to complex regulation (7). As
the Cdk1-Cyclin B1 complexes accumulate in S and G2
phases of the cell cycle, Myt1 and Wee1 kinases keep Cdk1
inactive by phosphorylating two neighboring residues in its
ATP-binding site: Thr-14 and Tyr-15 (8–10). At the G2/M
transition, the activation of Cdk1 is achieved by Cdc25 phos-
phatases, which dephosphorylate those two residues (11). The
exact trigger that activates the mitotic Cdk1-cyclin B1 com-
plexes remains unknown, but it is clear that the balance be-
tween the inhibiting Wee1/Myt1 kinases and the activating
Cdc25 phosphatases determines Cdk1 activity and hence mi-
totic entry.
In mammals, all three Cdc25 family members, Cdc25A,
Cdc25B, and Cdc25C, identified have been implicated in
the control of the G2/M transition through the activation of
Cdk1-cyclin B1 complexes (12–15). The initial stimulation of
Cdk1 has been attributed to Cdc25B (12), which acts on the
centrosomes (13, 16, 17). Cdc25A and Cdc25C complete the
activation of Cdk1-cyclin B1 as part of the autoamplification
loop, in which phosphorylation by Cdk1 activates Cdc25C
and stabilizes Cdc25A, thereby further increasing the phos-
phatase pool needed to reach the threshold of Cdk1 activity
required to enter mitosis (14, 18–20).
The highly conserved Cdc14 family of dual-specificity
phosphatases reverses CDK-dependent phosphorylation
events (21–23). In the budding yeast Saccharomyces cerevi-
siae, Cdc14 is essential for CDK inactivation at the exit of mi-
tosis (23, 24). Cdc14 is kept inactive in the nucleolus for most
of the cell cycle (24, 25), but at the onset of anaphase it is re-
leased from its nucleolar confinement by the sequential action
of the FEAR (fourteen early anaphase release) (26, 27) and
MEN (mitotic exit network) (28) regulatory networks. Active
Cdc14 promotes CDK inactivation by both promoting mitotic
cyclin destruction and CDK inhibitor Sic1 accumulation (23,
24). In the fission yeast Schizosaccharomyces pombe, the
Cdc14 homologue Flp1/Clp1 is released from the nucleolus
earlier in mitosis than S. cerevisiae Cdc14 and it is not essen-
tial for mitotic exit, although it does play roles in Cdk1/Cdc2
inhibition and in the regulation of septum formation and cy-
tokinesis (29–31). Flp1/Clp1 inhibits mitotic CDK activity by
promoting the phosphorylated state of Cdk1 at Tyr-15
through, at least in part, the direct down-regulation of Cdc25
protein (29–31).
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Cdc14 homologues have also been found in metazoans. In
the nematode Caenorhabditis elegans, genetic analysis have
suggested that Cdc14 probably promotes the stabilization of
the CDK inhibitor CKI-1, contributing to the G1 arrest of
specific precursor cells during larval development (32). In
humans, there are two Cdc14 homologues, termed Cdc14A
and Cdc14B (33), whose specific functions and substrates are
still poorly understood. During interphase, Cdc14A localizes
to the centrosome and Cdc14B to the nucleolus, but both are
dispersed at the onset of mitosis (22, 34). Previous studies
have shown that human Cdc14s are able to rescue cdc14 yeast
mutant phenotypes, suggesting some functional conservation
among these phosphatases (33, 35). Cdc14A has been identi-
fied as a regulator of centrosome duplication and has been
suggested to participate in the control of mitotic entry (34). In
addition, Cdc14A dephosphorylates human Cdh1, promoting
APC activation in vitro (36), suggesting that Cdc14A may also
regulate Cdk1 inactivation in human cells. Moreover, human
Cdc14A is a functional homologue of fission yeast Flp1/Clp1,
being able to dephosphorylate S. pombe Cdc25p both in vitro
and in vivo, like Flp1/Clp1 does (35). Here we investigated the
role of Cdc14A in cell cycle control, focusing on the regula-
tion of Cdc25s in human cells. We found that deregulated
human Cdc14A phosphatase impairs the timing of mitotic
entry by the effect on Cdk1-cyclin B1 activity. Furthermore,
Cdc14A inhibited both Cdc25A and Cdc25B catalytic activi-
ties at the G2/M transition. Thus, our results support a novel
role for human Cdc14A phosphatase as a regulator of Cdk1 at
the entry into mitosis.
EXPERIMENTAL PROCEDURES
Cell Culture—Derivatives of the U-2-OS cell line (51) con-
ditionally expressing Cdc14A alleles were a generous gift from
Jiri Lukas (Institute of Cancer Biology, Danish Cancer Soci-
ety). Cells were maintained and induced to express the trans-
genes as described previously (34). Wild type U-2-OS cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) plus 2 mM glutamine, 100 units ml1 penicillin G,
0.1 mg ml1 streptomycin, and 10% fetal bovine serum at
37 °C/5% CO2 and used for transient transfection experi-
ments. To synchronize cells in early S phase, thymidine was
added at 2.5 mM to subconfluent cells; 24 h later the cells were
washed with fresh culture medium, followed by a second ad-
dition of thymidine 12–15 h later. After 24 h of the second
thymidine treatment, cells were released by extensive
washing.
Flow Cytometry—For cell cycle analysis, cells were fixed in
ice-cold 70% ethanol for 1 h and stained with 8 g/ml-pro-
pidium iodide, 20 g/ml-RNase A solution for 1 h at 37 °C.
For phosphohistone H3 positivity, cells were harvested and
fixed in ice-cold 70% ethanol. Cells were washed with PBS-
0.15% Triton X-100 and subsequently stained with anti-phos-
phohistone H3 and FITC-conjugated anti-rabbit. Then, they
were incubated with a 8 g/ml propidium iodide and 20
g/ml RNase A solution for 1 h at 37 °C. Stained cells were
analyzed using a FACSCalibur device (Becton Dickinson).
Plasmids, siRNA and Virus Production—Aplasmid encoding
GST-Cdc14Awas a gift from Peter Jackson. GST-Cdc14Awas
purified from bacteria (22). Cdc14A(PD) is a mutant C278S,
which causes a complete loss of phosphatase activity. Full-length,
N-terminal (amino acids 1–373) and C-terminal (amino acids
374–566) Cdc25B fragments were amplified by PCR and fused
to an N-terminal HA-tag in pcDNA3 (Invitrogen). siRNAs
(Dharmacon) used were: Cdc25B (5-AAUCCUCCCUGUCGU-
CUGAAU-3), GL2 (control) (5-AACGUACGCGGAAUACU-
UCGA-3), Cdc14A siRNA 2 (5-GCACAGTAAATACCCACT-
ATT-3), Luc (control) (5-ACGUACGCGGAAUACUUC-
GAAUU-3). Cdc14A siRNA 1 (5-GGGACATTGATAGC-
CTGTTATGTAA-3) and its corresponding siRNA control
(low GC) were from Invitrogen. Cells were transfected with
Lipofectamine 2000 or Lipofectamine RNAiMAX reagents
(Invitrogen) according to the manufacturer’s instructions.
The final concentration of the siRNA duplex in the culture
medium was 60–100 nM. Four extra silent mutations were
introduced to Cdc14A cDNA in the area corresponding to
siRNA duplex 1 by polymerase chain reaction (PCR)
mutagenesis. The PCR oligos used are: 5-AGAACAGGG-
ACCCTGATCGCCTGCTATGTAATG-3 and 5-CATTA-
CATAGCAGGCGATCAGGGTCCCTGTTCT-3. The
resulting Cdc14A mutant (Cdc14A (R)) was subcloned into
pBABE-puro retroviral expression vector. Retroviruses
were produced in 293T cells and used to infect U-2-OS
cells. After 24 h of infection, cells were grown in medium
containing 0.5 g/ml of puromicine for 48 h and then
transfected with the corresponding siRNAs. pBABE-puro-
GFP plasmid was used to control the infection efficiency.
mRNA Analyses—RNA was extracted using the RNeasy kit
(Qiagen). cDNA synthesis was performed using SuperScript
First-Strand kit (Invitrogen). Cdc14A primers were 5-GTTC-
CTGAACATCTGTGA-3 and 5-GCATGTGTAAACCTG-
TAG-3. Cdc14B primers were 5-GTGCCATTGCAGTA-
CATT-3 and 5-AGCAGGCTATCAGAGTG-3. 18 S rRNA
primers, used as internal control, were 5-CGCCGCTAGAG-
GTGAAATTC-3 and 5-CTTTCGCTCTGGTCCGTCTT-
3. Quantitative PCR analysis was performed according to
standard procedures using an iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad).
Immunochemical Techniques—The antibodies used in this
study included mouse monoclonal to Cdc14A (DCS-291,
NeoMarkers), Cdc25A (sc-7389, Santa Cruz Biotechnology),
Cdc25B (DCS-164, (52), Myc tag (sc-40, Santa Cruz Biotech-
nology), Cdk1 (sc-54, Santa Cruz Biotechnology), -actin
(AC-15, Sigma), rabbit polyclonals to Cdc25A (sc-7157),
Cdc25B (sc-5619), Cdc25C (sc-327), cyclin A (sc-751), cyclin
B1 (sc-752), GFP (FL), and HA (Y-11), all from Santa Cruz
Biotechnology, and phospho-Cdk1-Tyr15 (9111, Cell Signal-
ing) and phosphohistone H3-Ser10 (Upstate). Immunopre-
cipitation, immunoblotting, and Cdc25 phosphatase assays
were performed as described (52).
Kinase and Phosphatase Assays—Immunoprecipitated N-
and C-terminal halves of Cdc25B were phosphorylated by
Cdk1-cyclin B1 (New England Biolabs) in the presence of 0.15
Ci of [-32P]ATP. Samples were then incubated for 30 min
at 30 °C with GST-Cdc14A or GST-Cdc14A(PD) (100 ng) in
phosphatase buffer (20 mM Tris, pH 8.3; 150 mM NaCl, 2 mM
EDTA, 0.1% Triton X-100; 5 mM DTT), or with  phospha-
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tase (New England Biolabs) according to the manufacturer’s
instructions. To measure Cdk1 activity, Cdk1-cyclin B1 com-
plexes were immunoprecipitated from cellular extracts using
anti-cyclin B1 antibodies. Then, they were incubated for 15
min at 30 °C with histone H1 in kinase buffer (50 mM Hepes
pH 7.5, 10 mM MgCl2, 1 mM DTT) in the presence of
[-32P]ATP. Reactions were stopped by the addition of load-
ing buffer and boiled for 5 min at 95 °C. Proteins were re-
solved by SDS-PAGE and visualized by immunoblotting or
autoradiography. Cdc25 phosphatase activities were mea-
sured as activation of Cdk1-cyclin B1 complexes as described
previously (52). Briefly, inactive Cdk1-cyclin B1 complexes
were immunoprecipitated from cells treated with doxorubicin
using anti-cyclin B1 antibodies. Cdc25 proteins were immu-
noprecipitated with specific antibodies and incubated for 45
min at 30 °C with Cdk1-cyclin B1 immunoprecipitates in
phosphatase buffer. Reaction was stopped by addition of ki-
nase assay buffer. Then, to assay the activity of Cdk1, kinase
reactions were carried out in the presence of [-32P]ATP for 5
min using histone H1 as substrate.
Immunofluorescence Microscopy—Cells were grown on cov-
erslips, induced to express Myc-Cdc14A for 48 h and fixed for
20 min in 100% methanol at20 °C. Myc-tagged Cdc14A
was detected with rabbit polyclonal antibody against Myc
tag (clone 9E10; Sigma-Aldrich). Centrosomes were de-
tected by co-staining with mouse monoclonal antibody
against -tubulin (clone GTU-88; Sigma-Aldrich). Second-
ary antibodies were Alexa Fluor 488 goat anti-mouse (In-
vitrogen) and FITC-conjugated goat anti-rabbit (Jackson
ImmunoResearch Laboratories). DNA was counterstained
by DAPI. Images were acquired using a 40 or 60 objec-
tives under a Leica DM6000B microscope and a digital
camera (Hamamatsu ORCA-ER) and processed with Meta-
morph program.
Live Cell Imaging—Human BJ cells were grown in six well
plates. Cells were synchronized in G1/S by double thymidine
treatment and transfected with Cdc14A, or control siRNAs
after the first thymidine arrest. Cells were then released into
fresh medium containing the kinesin Eg5 inhibitor, Dimethyl-
enastron (10 M), to prevent exit from mitosis, and trans-
ferred to the microscope. Recording was started right after
release from the second thymidine treatment. For rescue of
Cdc14A knockdown experiments, U-2-OS cells were first
infected with the corresponding retroviruses and then
treated as above. Nocodazole (50 nM) was used instead of
dimethylenastron. Time-lapse frames were acquired using
a 20 EC Plan-Neofluar objective on an Eclipse TE2000-E
microscope (Nikon) controlled by Metamorph software
and equipped with a Control Unit of temperature, air, and
CO2 (Okolab), and a Hamamatsu ORCA-ER camera.
Bright-field frames were recorded every 5 min. Time-lapse
data were processed using Metamorph and ImageJ 1.42q
software.
RESULTS
Ectopic Expression of Cdc14A Delays the Onset of Mitosis—
Using U-2-OS clones expressing Myc-tagged Cdc14A or its
phosphatase-dead (PD) mutant form in a tetracycline-re-
pressible manner (34), we observed that induction of active
Cdc14A, but not the inactive Cdc14A(PD), delayed cells in
G2/M (Fig. 1, A and B). This effect was correlated with an
inhibitory effect on mitotic Cdk1-cyclin B1 complexes (Fig.
1C). In these cells, we also checked the cell cycle-regulated
localization of Myc-Cdc14A, which was, as it has been de-
scribed (22), centrosomal during interphase and cytosolic
since early prophase to the end of mitosis (supplemental
Fig. S1). Previously reported effects of Cdc14A overexpres-
sion, such as lagging and missegregated chromosomes,
misshapen nuclei, progressive cell death, and centrosome
splitting out of mitosis (34) were also observed (supple-
mental Fig. S2).
To define the cell cycle delay caused by Cdc14A overex-
pression more precisely, cells were synchronized in G1/S by
double thymidine treatment, and then released and moni-
tored as they progressed through G2/M. Cdc14A expression
was induced as indicated in the experimental setup depicted
in Fig. 2A. As shown in Fig. 2B, the ectopic expression of ac-
tive Cdc14A, led to a higher number of cells with a 4N DNA
at all the time points analyzed as compared with non-induced
cells or cells overproducing the inactive phosphatase form,
indicating that Cdc14A up-regulation slows cells in G2/M.
The same effect was observed when Cdc14A expression was
induced after the second thymidine treatment (supplemental
Fig. S3). Because cyclin A starts to be degraded in promet-
aphase (37, 38) and cyclin B1 in metaphase (39), we used
these two proteins as markers for the characterization of the
G2/M delay. As shown in Fig. 2C, while in control cells cyclin
A declined 14 h after release, in cells overexpressing Cdc14A
the level of cyclin A remained constant, indicating a delay
FIGURE 1. Ectopic expression of Cdc14A results in G2/M delay. A, U-2-OS
cell lines conditionally expressing active Cdc14A or its phosphatase-dead
form, Cdc14A(PD), following removal of tetracycline from the medium (T)
were analyzed by flow cytometry at the indicated time points. Untreated
parental U-2-OS cells were also monitored as control. B, Cdc14A U-2-OS cell
lines induced as in Awere subjected to immunoblot analysis with the indi-
cated antibodies. C, Cdk1-cyclin B1 complexes were immunoprecipitated
with anti-cyclin B1 antibody from cells induced to express Cdc14A for 48 h.
The ability of these complexes to phosphorylate histone H1 was assessed in
the presence of [-32P]ATP and normalized by the amount of immunopre-
cipitated Cdk1. Cdk1-cyclin B1 activity in non-induced cells (T, control
conditions) was considered 100%. Left panels correspond to a representa-
tive experiment. Bars in the graph showmeans from three independent
experiments.
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before prometaphase. Consistently, cyclin B1 levels also re-
mained high throughout the experiment in cells overproduc-
ing Cdc14A. In parallel, we monitored the phosphorylation
shift of Cdk1 by immunoblot. While in control cells the non-
phosphorylated form of Cdk1 was significantly increased 14 h
after release, indicating Cdk1 activation, in cells overexpress-
ing Cdc14A phosphorylated and inactive Cdk1 persisted up to
the last time point (Fig. 2C). This observation was confirmed
FIGURE 2. Cells overexpressing active Cdc14A accumulate before prophase. A, scheme of the experimental setup used to induce Cdc14A or Cdc14A(PD)
expression in cells synchronized at G1/S. Before the second thymidine treatment, half of the cells were induced to express the transgenes removing tetracy-
cline from the medium (T) and the other half were kept non-induced (T). Samples were taken for flow cytometry (B), immunoblot (C), kinase assays
(D), and chromosome condensation (E) analyses at the indicated times after release. B, FACS profiles of synchronized cells. Samples of induced and non-
induced cells were taken for FACS analysis at 0, 10, 14, 15, and 17 h after release from the double thymidine treatment. C, cellular extracts from the U-2-OS
cell line conditionally expressing active Cdc14A, synchronized, and induced to express the transgene or kept non-induced as indicated in A, were prepared
at the indicated times and immunoblotted with the indicated antibodies. P: phosphorylated; NP: non phosphorylated. D, Cdk1-cyclin B1 complexes were
immunoprecipitated from cellular extracts corresponding to 14- and 15-h samples of C using anti-cyclin B1 antibodies. Then, their activity was determined
by their capacity to phosphorylate histone H1 in the presence of [-32P]ATP. The upper gel shows 32P incorporation, and the lower panel the amount of im-
munoprecipitated Cdk1 detected by immunoblot. E, U-2-OS cells conditionally expressing active Cdc14A were grown on glass coverslips and treated as
indicated in A. Cells were taken at the indicated times after release, fixed, stained with 4,6-diamidino-2-phenylindole, and analyzed by microscopy. More
than 1000 cells were analyzed per time point.
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by in vitro Cdk1 kinase assays (Fig. 2D). These results show
that Cdc14A inhibits Cdk1-cyclin B1 complexes activity at the
G2/M transition.
Because chromosome condensation is an early event in mi-
tosis and depends on Cdk1 activity (5), we wondered whether
the kinetics of chromosome condensation might be affected
by ectopic expression of Cdc14A. As shown in Fig. 2E, in cul-
tures in which Cdc14A was up-regulated chromosome con-
densation was also consistently delayed.
Expression of the Cdc14A(PD) form did not cause, how-
ever, any delay at the G2/M transition, as observed by mea-
suring cyclin B1 degradation, Cdk1 activation and chromo-
some condensation (supplemental Fig. S4). Taken together,
these data indicate that the excess of active Cdc14A delays the
G2/M transition, suggesting that Cdc14A regulates mitotic
entry.
Depletion of Cdc14A Accelerates Entry into Mitosis—To
confirm the possible role of Cdc14A in mitotic entry, we
down-regulated Cdc14A expression using small interfering
RNA (siRNA) in U-2-OS cells (Fig. 3A). Cells were synchro-
nized in G1/S by double thymidine treatment and transfected
with Cdc14A or control siRNAs after the first thymidine ar-
rest. Cells were then released into fresh medium containing
nocodazole, to prevent exit from mitosis, and were monitored
as they progressed into mitosis. Because the available
Cdc14A-specific antibodies did not recognize the endogenous
protein, siRNA oligos were validated by RT-PCR, checking
the two Cdc14 isoforms, Cdc14A and Cdc14B. As shown in
FIGURE 3.Down-regulation of Cdc14A accelerates mitotic entry. A, outline of the experimental setup used to transfect cells with siRNAs. U-2-OS cells
released from a first thymidine treatment were transfected with Cdc14A or control siRNAs and grown for 15 h, after which they were subjected to a second
thymidine treatment for 24 h. Next, the cells, synchronized at early S phase, were released into the cell cycle by the addition of fresh medium containing
nocodazole to prevent mitotic exit. Cells were then collected at the indicated times for chromosome condensation (C), immunoblotting (D), and phospho-
histone H3 positivity (E) analyses. B, Cdc14A and Cdc14B mRNA levels were analyzed at 10 h after release using real-time PCR in triplicate measurements
(S.D.). The value given for Cdc14A and Cdc14B mRNAs in control cells was set as 1. C, cells were fixed and stained with 4,6-diamidino-2-phenylindole and
analyzed by fluorescence microscopy. The percentage of cells with condensed chromosomes was obtained by counting a minimum of 800 nuclei for each
sample. D, cells were collected at the indicated times and then cell lysates were immunoblotted with antibodies to the indicated proteins. The graph shows
the quantification of dephosphorylated/phosphorylated Cdk1 forms shown in D at the indicated time points. The results of C and D correspond to the same
experiment and are representative of three independent ones. E, phosphohistone H3 positivity was determined by flow cytometry, using anti-phosphohis-
tone H3/FICT antibodies. The graph shows the quantification of three independent experiments.
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Fig. 3B, Cdc14A siRNAs (siRNA 1) were efficient and specific
against this transcript. We found that the kinetics of chromo-
some condensation was accelerated when Cdc14A was down-
regulated as compared with control cultures (Fig. 3C). Consis-
tently, depletion of Cdc14A also accelerated Cdk1 activation
and histone H3 phosphorylation (Fig. 3, D and E), indicating
that entry into mitosis was faster in Cdc14A
siRNA-transfected cells.
Because specificity is a major concern for siRNA duplexes,
to strengthen the conclusion that Cdc14A slows the entry
into mitosis, two types of experiments were performed. First,
we down-regulated Cdc14A by an independent siRNA duplex
(siRNA 2). Under similar experimental conditions, siRNA 2
also accelerated chromosome condensation (supplemental
Fig. S5, A and B). Moreover, the effect obtained with siRNA 2
was less marked than with the first siRNA duplex, consistent
with a lower Cdc14A depletion (Fig. 3B and supplemental Fig.
S5, A and C). These results suggest that Cdc14A is a rate-lim-
iting factor for the entry into mitosis. Second, we performed a
siRNA-resistant transgene rescue experiment for siRNA 1,
using a Cdc14A cDNA with several silent mutations in the
sequence corresponding to siRNA 1 as the rescue construct
(Cdc14A(R)) (Fig. 4A). U-2-OS cells were first infected with
retroviruses expressing pBABE empty vector or pBABE-
Cdc14A(R) and then transfected with siRNA 1 or siRNA con-
trol as indicated in Fig. 3A. Entry into mitosis was monitored
by time-lapse microscopy. As shown in Fig. 4B, cells infected
with empty vector and transfected with siRNA 1 accelerated
entry into mitosis as judged by the faster accumulation of mi-
totic cells. However, in cells infected with retroviruses ex-
pressing Cdc14A(R), and then transfected with siRNA 1 the
kinetics of mitotic cells accumulation was similar to the ob-
served in the control siRNA-treated cells (Fig. 4B). We con-
clude that the faster entry into mitosis caused by siRNA 1 is
specific to knockdown of Cdc14A.
To know whether or not Cdc14A also regulates the mitotic
entry in normal, nontransformed human cells, we analyzed
whether Cdc14A depletion in human BJ-TERT fibroblasts
would also accelerate the entry into mitosis. Upon transfec-
tion with Cdc14A or control siRNAs as described in Fig. 3A,
we found that reduction of Cdc14A in these cells also resulted
in a faster mitotic entry (Fig. 5, A and B). All together, these
data indicate that, in a normal cell cycle, Cdc14A negatively
regulates entry into mitosis.
Cdc14A Dephosphorylates Cdc25B and Inhibits Its Catalytic
Activity—We wished next to investigate the molecular mech-
anism by which Cdc14A negatively regulates entry into mito-
sis. Because we found no direct effect on Cdk1-Cyclin B1
complexes (data not shown), we speculated that Cdc14A
FIGURE 4. Expression of siRNA-resistant Cdc14A in Cdc14A
siRNA-treated cells restores the timing of mitotic entry. A, U-2-OS cells
infected with retroviruses expressing Cdc14A wild type (pBABE-Cdc14A WT)
or Cdc14A cDNA with four silent mutations in the sequence corresponding
to siRNA sequence (pBABE-Cdc14A(R)) were transfected with control or
Cdc14A siRNA. After 48 h of transfection, cell lysates were immunoblotted
for Cdc14A or actin. B, U-2-OS cells infected with empty vector (pBABE) or
retroviruses expressing Cdc14A(R) were synchronized in G1/S by double
thymidine treatment and transfected with Cdc14A or control siRNAs after
the first thymidine arrest as described in the legend to Fig. 3A. Cells were
then released into fresh medium containing nocodazole and monitored
as they progressed into mitosis by time-lapse microscopy. Recording was
started right after release. Accumulative plots of cells that enter in mitosis,
judged by cell rounded-up, are shown in percentage of the total number of
cell in each case (n 201, n 227, and n 161 for pBABE/control siRNA,
pBABE/Cdc14A siRNA, and pBABE-Cdc14A(R)/Cdc14A siRNA, respectively).
The results are representative of three independent experiments.
FIGURE 5.Down-regulation of Cdc14A accelerates mitotic entry in BJ
human fibroblasts. Cells were synchronized in G1/S by double thymidine
(5 mM) treatment and transfected with Cdc14A (siRNA 1) or control siRNAs
after the first thymidine arrest as described in the legend to Fig. 3A. Cells
were then released into fresh medium containing the kinesin Eg5 inhibitor,
Dimethylenastron (10 M), to prevent exit frommitosis, and were moni-
tored as they progressed into mitosis by time-lapse analysis. Recording was
started right after release. The results are representative of three indepen-
dent experiments. A, quantification of time-lapse series. Accumulative plots
of cells that enter in mitosis, judged by cell rounded-up, are shown in per-
centage of the total number of cell in each case (n 239 and n 240 for
control and Cdc14A siRNAs, respectively). B, Cdc14A and Cdc14B mRNA
levels were analyzed when cells were released from the second thymidine
treatment using real-time PCR in triplicate measurements (S.D.). The value
given for Cdc14A and Cdc14B mRNAs in control cells was set as 1.
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might regulate Cdc25 mitotic activators. The fact that
Cdc14A is able to dephosphorylate in vitro and to inhibit in
vivo Cdc25 protein in S. pombe cells (35) supported this hy-
pothesis. To test this idea, we first checked Cdc14A binding
to each of the Cdc25s. Cdc14A was co-expressed with
Cdc25A, -B, or -C in U-2-OS cells and analyzed by co-immu-
noprecipitation. Cdc14A co-immunoprecipitated with
Cdc25B, but not with Cdc25A or Cdc25C (Fig. 6A). Further-
more, Cdc14A also bound to endogenous Cdc25B (Fig. 6B),
suggesting that it may be a substrate of Cdc14A. Indeed, only
the faster migrated, non-modified form of Cdc25B was ob-
served in U-2-OS cells conditionally expressing high levels of
wild-type Cdc14A, whereas cells expressing the inactive
Cdc14A(PD) mutant exhibit both the modified and non-mod-
ified forms (Fig. 6C).
To confirm Cdc25B dephosphorylation by Cdc14A, full-
length Cdc25B or its N- or C-terminal halves were subjected
to in vitro phosphatase assays using GST-Cdc14A or  phos-
phatase. The Cdc25B N-terminal half contains the known
CDK phosphorylation sites. As shown in Fig. 7A, both full-
length and N-terminal Cdc25B, but not the C-terminal do-
main, were equally modified by both the Cdc14A and  phos-
phatase treatments, suggesting that Cdc14A
dephosphorylates the Cdc25B N-terminal domain. This is
consistent with the notion of Cdc14A phosphatase removing
CDK-dependent phosphorylation events. Next, the two N-
and C-terminal halves of Cdc25B, immunoprecipitated as
HA-tagged protein constructs from U-2-OS-transfected cells,
were first phosphorylated in vitro by Cdk1-cyclin B1, and then
incubated with the GST-Cdc14A or its inactive GST-
Cdc14A(PD) form. As shown in Fig. 7B, only the N-terminal
half of Cdc25B was phosphorylated by Cdk1-cyclin B1 and
was efficiently dephosphorylated by Cdc14A. Together, these
data indicate that Cdc14A directly binds to and dephosphory-
lates Cdk1-dependent phosphorylation sites of Cdc25B.
Because Cdc25B activity peaks at G2/M, coinciding with its
phosphorylated state, we surmised that Cdc14A might regu-
FIGURE 6. Cdc14A interacts with Cdc25B. A, U-2-OS cells were cotrans-
fected with GFP-tagged Cdc14A and each of the HA-tagged Cdc25 proteins
as indicated. Cdc14A-Cdc25 interactions were assessed by immunoblotting
of HA-immunocomplexes with anti-GFP antibody.WCE, whole cell extracts.
B, cells were transfected with GL2 (control) or Cdc25B siRNAs for 48 h and
transfected with Myc-Cdc14A plasmid for an additional 24 h. Cell lysates
were subjected to immunoprecipitation with Cdc25B antibody followed by
immunoblotting with the indicated antibodies. C, U-2-OS-Cdc14A cell lines
were left untreated or induced to express the transgenes for 48 h. Cell ly-
sates were processed for immunoblotting with the indicated antibodies.
Asterisks show cross-reacting bands.
FIGURE 7. Cdc14A dephosphorylates and inhibits Cdc25B. A, full-length,
N-, or C-terminal Cdc25B forms were expressed in U-2-OS cells for 24 h, im-
munoprecipitated with anti-HA antibody, and incubated with GST-Cdc14A
or  phosphatase. Dephosphorylation of Cdc25B was monitored by immu-
noblotting. B, Cdc25B-N or -C immunocomplexes, prepared as in A, were
incubated with recombinant Cdk1-cyclin B1 and [-32P]ATP, and then with
GST-Cdc14A or GST-Cdc14A(PD) forms. Phosphorylated proteins were visu-
alized by autoradiography. C, U-2-OS-Cdc14A cell lines were left untreated
or induced to express the transgenes for 48 h. Cells were then processed for
the measurement of Cdc25B activity on Cdk1-cyclin B1 complexes, whose
activation was then measured by kinase assays on histone H1. The input
lane shows the activity of Cdk1-cyclin B1 not incubated with Cdc25B. D, U-
2-OS cells were synchronized and transfected as described in the legend to
Fig. 3A. Cells were collected at 12 h after release and processed for Cdc25B
activity analysis. The results correspond to the 12-h release samples of Fig. 3
and are representative of two independent experiments. E, Cdc25B was
immunoprecipitated from U-2-OS cells and incubated with GST-Cdc14A
forms. The samples were then divided and processed for the immunoblot-
ting of Cdc25B or the measurement of Cdc25B activity.
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late it. To address this issue, we first analyzed the activity of
Cdc25B in cells overexpressing Cdc14A. Thus, Cdc25B was
immunoprecipitated from U-2-OS cells conditionally express-
ing Cdc14A or the inactive Cdc14A(PD) form, and its phos-
phatase activity was assessed by their ability to dephosphor-
ylate inactive Cdk1-cyclin B1 complexes, whose activation
was then measured by kinase assays on histone H1. We found
that Cdc25B was inhibited in cells overexpressing active
Cdc14A but not the Cdc14A(PD) mutant form (Fig. 7C), indi-
cating that Cdc14A negatively regulates Cdc25B activity.
Next, we determined whether the down-regulation of Cdc14A
expression affects Cdc25B activity at the G2/M transition.
Indeed, when the Cdc25B activity was tested in G2/M syn-
chronized cells treated with Cdc14A siRNA (Fig. 3B) we
found that it was significantly increased (Fig. 7D). Finally, in
order to check that Cdc25B inhibition was in fact a direct ef-
fect of Cdc14A activity, immunoprecipitated Cdc25B from
untreated U-2-OS cells was subjected to in vitro phosphatase
assays with both GST-Cdc14A or the inactive GST-
Cdc14A(PD) form. Cdc25B activity was then assessed on in-
active Cdk1-cyclin B1 complexes. As shown in Fig. 7E, the in
vitro Cdc14A-mediated dephosphorylation of Cdc25B led to a
dramatic inhibition of its activity. Together, these data indi-
cate that Cdc14A dephosphorylates Cdc25B, inhibiting its
catalytic activity.
Cdc14A Regulates the Activity of Cdc25A—As mentioned,
the three Cdc25 isoforms are involved in the activation of
Cdk1 at the G2/M transition. We therefore also analyzed the
ability of Cdc14A to regulate Cdc25A and Cdc25C at mitotic
entry. Neither protein levels nor the subcellular locations of
Cdc25A and Cdc25C were modified when cells misexpressed
Cdc14A (Figs. 3D and 5C, and data not shown). Cdc25A and
Cdc25C activities were also analyzed in cells in which Cdc14A
was deregulated. Thus, both Cdc25A and Cdc25C proteins
were immunoprecipitated with specific antibodies from asyn-
chronous U-2-OS cells conditionally expressing Cdc14A, and
their activity was assessed on inactive Cdk1-cyclin B1 com-
plexes. Surprisingly, while Cdc25C was not affected (data not
shown), the activity of Cdc25A was significantly decreased in
cells overexpressing Cdc14A (Fig. 8A). Because the induction
of the catalytic dead form of Cdc14A did not have any effect
(Fig. 8B), we surmised that the inhibition of Cdc25A would
depend on Cdc14A activity. Moreover, we determined
whether the Cdc14A-mediated inhibition of Cdc25A oc-
curred at the G2/M boundary. We found that in G2/M-syn-
chronized cells Cdc25A activity was inhibited when Cdc14A
was overexpressed (Fig. 8C), indicating that Cdc14A inhibits
Cdc25A activity at the G2/M transition. Again, Cdc25C activ-
ity was not significantly affected under these experimental
conditions (Fig. 8D). Finally, if the inhibition of Cdc25A activ-
ity is mediated by Cdc14A, the opposite effect should be re-
flected in cells where Cdc14A is down-regulated. Indeed,
when the Cdc25A activity was tested in G2/M-synchronized
cells treated with Cdc14A siRNA (Fig. 3B), we found that it
was significantly increased (Fig. 8E). We have previously re-
ported that Cdc14A reverses the Cdk1-cyclin B1 phosphory-
lation of Cdc25A on residues involved in its stability (40). In-
deed, in vitro dephosphorylation of Cdc25A by Cdc14A does
not inhibit its catalytic activity (data not shown). Taken to-
gether, our results suggest that at the G2/M transition
Cdc14A acts on an unknown protein, which in turn inhibits
Cdc25A phosphatase activity.
DISCUSSION
The results presented here demonstrate that misregulation
of Cdc14A phosphatase in the cell affects the onset of mitosis,
indicating that Cdc14A modulates the G2/M transition. In
this sense, we found that when both asynchronous and G2-
phase synchronized cells had increased levels of active
Cdc14A phosphatase they accumulated at the G2/M
boundary and slowly progressed through the early stages of
mitosis. Moreover, cells where Cdc14A expression was
down-regulated by siRNAs accelerated entry into mitosis
and this effect can be rescued by an RNAi-resistant trans-
gene. These data indicate that Cdc14A is involved in the
timing of the G2/M transition in human cells. It has been
reported that the overexpression of the other human
FIGURE 8. Cdc14A regulates Cdc25A activity. A and B, U-2-OS-Cdc14A
clones were left untreated or induced to express Cdc14A or Cdc14A(PD) for
48 h. Cells were then processed for measurement of Cdc25A activity. Phos-
phorylated bands were quantified and normalized with respect to immuno-
precipitated Cdc25A. The Cdc25A activity from untreated cells (T) was
considered 100%. The graph represents the means from three independent
experiments. C and D, U-2-OS-Cdc14A cell line was synchronized and
treated as in the legend to Fig. 2A. Cdc25A and Cdc25C activities were ana-
lyzed from 14 h samples. C, result shown in the left panel corresponds to the
14 h samples of Fig. 2. The graph shows the quantification of three inde-
pendent experiments. The value given for the Cdc25A activity in the control
samples was set as 100%. D, Cdc25C activity was analyzed from the same
samples as in C. E, U-2-OS cells were synchronized and transfected with
Cdc14A siRNA as described in the legend to Fig. 3A. Cdc25A activity was
analyzed from 12 h samples. The result is representative of two indepen-
dent experiments and corresponds to the 12 h samples of Fig. 3.
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Cdc14 family member, Cdc14B, does not have a major ef-
fect on the distribution of cells in different parts of the cell
cycle (34). Thus, the observed effects seem to be specific
for Cdc14A phosphatase.
The key switch for the onset of mitosis is the activation of
cyclin-dependent kinase Cdk1 (41). Because yeast Cdc14 ho-
mologues have been shown to negatively regulate Cdk1 activ-
ity (23, 24, 29, 31, 42), we reasoned that the effect produced
by Cdc14A misregulation at the G2/M transition could be due
to its role in Cdk1 regulation. In fact, high levels of Cdc14A in
the cell inhibited the Cdk1-cyclin B1 complexes activity (Fig.
1C). We investigated the mechanism by which Cdc14A regu-
lates Cdk1 activity. Because we did not find evidence for a
direct effect of Cdc14A on Cdk1-cyclin B1 complexes, we an-
alyzed whether Cdc14A phosphatase might act through their
regulators, the Cdc25 phosphatase family. In mammalian
cells, all three Cdc25 isoforms contribute to achieving and
maintaining the high activity of Cdk1-cyclin B1 complexes at
mitosis (12–15, 43) (see Ref. 44 for a review). It is accepted
that Cdc25B starts the activation of Cdk1-cyclin B1 at centro-
somes at the G2/M transition (13, 16, 17). Later on, Cdc25A
and Cdc25C complete Cdk1-cyclin B1 complexes activation
as a part of the autoamplification loop, in which phosphoryla-
tion by Cdk1 activates Cdc25C and stabilizes Cdc25A, which
in turn cooperate to reach the threshold of mitotic Cdk1 ac-
tivity (14, 18–20). We therefore speculated that Cdc14A
could control Cdk1 activation by acting on these Cdk1 regula-
tory proteins.
First, we demonstrate that Cdc14A interacts with and de-
phosphorylates Cdc25B at Cdk1-cyclin B1 phosphorylation
sites contained within its N-terminal domain, inhibiting its
catalytic activity. Phosphorylation of Cdc25B has been re-
ported to coincide with an increase in its phosphatase activity
at the G2 and M phases (12, 45). Several kinases seem to be
involved in this Cdc25B activation among which are Aurora A
and CK2 (46, 47). We show that Cdc14A inhibits Cdc25B ac-
tivity by reversing Cdk1-cyclin B1-mediated phosphorylation.
Our data indicate that Cdk1 phosphorylates and activates
Cdc25B at mitosis. Thus, we have identified a new substrate
of Cdc14A, the Cdc25B protein, whose inhibitory dephosphor-
ylation by Cdc14A leads to a decrease in Cdk1 activity at the
onset of mitosis. Because both Cdc14A and Cdc25B localize
to centrosomes at some point during the cell cycle, it will be
of interest to understand whether the regulation of Cdc25B
activity by Cdc14A occurs in centrosomes or whether is per-
formed by the centrosome-released pool of Cdc14A at early
mitosis.
Moreover, we show that misregulation of Cdc14A produces
a change in the catalytic activity of Cdc25A. Thus, in G2/M-
synchronized cells, high levels of Cdc14A induced a signifi-
cant reduction in Cdc25A catalytic activity, whereas the
down-regulation of endogenous Cdc14A produced the oppo-
site effect, i.e. an increase in its phosphatase activity. This was
indeed the most intriguing finding of our study. To date, the
regulation of Cdc25A at the G2 and M phases seems to be
tightly associated with its protein turnover or stability (48).
Accordingly, Cdc25A protein levels change in a cell cycle-de-
pendent manner, being predominantly expressed in G1 (49)
and stabilized in mitosis through Cdk1-cyclin B1-mediated
phosphorylation (14). In contrast, destruction of Cdc25A pre-
vents premature mitosis of cells with an incompletely repli-
cated and/or damaged genome (for a review, see Ref. 50). Our
results demonstrate that Cdc14A affects the activity of
Cdc25A and not its stability at the G2/M transition. These
data suggest a new mechanism of Cdc25A regulation at G2/M
boundary, based on changes in its catalytic activity mediated
by Cdc14A phosphatase. We have previously reported that
Cdc14A reverses the Cdk1-cyclin B1 phosphorylation of
Cdc25A on residues involved in its stability (40). Indeed, in
vitro dephosphorylation of Cdk1-cyclin B1-phosphorylated
Cdc25A by Cdc14A did not inhibit its catalytic activity (data
not shown). Our results suggest that at the G2/M transition
exists an inhibitory effect of Cdc14A on Cdc25A, which might
likely involve an unknown protein modulating the activity of
Cdc25A phosphatase.
It has been shown that Cdc25A and Cdc25B are required
for mitotic entry (13, 14). Cdc25A is involved in the initiation
of chromosome condensation and Cdc25B initiates the acti-
vation of Cdk1-cyclin B1 at centrosomes (13). In summary, we
show that depletion of Cdc14A accelerates the timing of mi-
totic entry through deregulation of Cdc25A and Cdc25B at
the G2/M transition. Cdc14A inhibits Cdc25A and Cdc25B
activity, the latter through direct binding and dephosphory-
lation (Fig. 9). Our findings indicate that in human cells
Cdc14A plays a role in preventing premature entry into
mitosis.
FIGURE 9.Model: function of Cdc14A at the G2/M transition. In late G2
Cdc14A is proposed to negatively regulate Cdk1 activation to control the
timing of mitosis by inhibiting Cdc25A and Cdc25B activities. Cdc14A inhib-
its Cdc25A activity through an unknownmechanism. Cdc14A directly binds
to and dephosphorylates Cdc25B.
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